Business Context and Reporting Period
Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) filed a Form 8-K on August 6, 2025, to announce financial results for the quarter ended June 30, 2025. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached press release (Exhibit 99.1), which is not included in the provided text.
Material Changes
The filing text does not disclose specific material changes versus the prior comparable period. The document serves as a notification that results were issued but does not summarize the comparative data.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or unusual items. It explicitly states that the information in the attached press release is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2025 financial figures.
- Verify cash runway and burn rate given the absence of liquidity data in the 8-K text.
- Confirm any updates to clinical trial milestones or regulatory status mentioned in the press release.
- Check for any forward-looking statements or guidance revisions in the attached exhibit.